Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 28;13(1):92. doi: 10.1038/s41419-022-04531-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — A mRNA levels of USP family members in IM-resistant strain K562-R and its parent cell line K562 were detected by qPCR. B qPCR detection of mRNA levels of USP4, USP6, USP9x, and USP39 in clinical samples (bone marrow aspiration specimens from 15 normal controls, 20 patients with IM-sensitive CML, and 20 patients with IM-resistant CML, Cohort 1). C, D Western blot detection of levels of USP6 in nine clinical samples from Cohort 1 (three from each group). E The mRNA level of USP6 in clinical samples (bone marrow specimens from 15 normal controls and 85 patients with CML, Cohort 2). F Survival analysis was performed between patients with CML with low-USP6 or high-USP6 expression in Cohort 2 (log-rank test). **P < 0.01, ***P < 0.001.